Heterocyclic modulators of HIF activity for treatment of disease

A compound having structural Formula II

• or a salt thereof, wherein:
• X2, X4, and X5 are independently selected from the group consisting of CR21, N, O, and S, and wherein X2, X4, and X5, taken together, form a 5-membered heteroaryl;
• two of X2, X4, and X5 are N;
• and one of X2, X4, and X5 is O;
• or
• one of X2, X4, and X5 is N;
• one of X2, X4, and X5 is O;
• and one of X2, X4, and X5 is CH;
• Z1 and Z2 are independently selected from the group consisting of N, NR1, C═O, and CR1;
• at least one of Z1 or Z2 is CR1;
• Z3 is selected from the group consisting of N, NR12, C═O, and CR12;
• R1 is selected from the group consisting of
• hydrogen, deuterium, fluorine, bromine, cyano, methyl, isopropyl,
• ethylene,
• trifluoromethyl, bromomethyl, hydroxymethyl, difluoromethoxy, methoxy, ethoxy, isopropoxy, hydroxy, nitro, acetyl, carboxyl, —CO2CH3,
• —SO2CH3, —SO2CH2CH3, SO2CH2CH2CH3, —SO2NH2,
• amino, methylamino, dimethylamino,
• R12, R13, and R14 are hydrogen;
• R16, R19, and R20 are hydrogen;
• R17 is hydrogen;
• R18 is selected from the group consisting of
• hydrogen, deuterium, halogen, methyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, acetyl, hydroxymethyl, methoxymethyl, methoxy, isopropoxy, methylamino, dimethylamino, methylthio, cyanomethyl, cyanomethylthio, cyano, —SO2CH3, —SO2CH(CH3)2, —SO2CH2CH(CH3)2, —SO2NHCH2CH2CH3, —SO2CHF2, —SO2CF3,
• trifluoromethyl, trifluoromethylthio, difluoromethoxy, and trifluoromethoxy;
• R21 is selected from the group consisting of null, hydrogen, deuterium, halogen, and alkyl;
• R22 is selected from the group consisting of hydrogen, deuterium, methyl, acetyl,
• and
• R23 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, 3-pyridyl, and cyclopropyl.